STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2315 by analyst upside · 2026-08-13
BVS
Bioventus Inc.
Healthcare · Market Cap $1B · P/E 17.8x
ANALYST PRICE TARGET
+20.7%
implied upside to consensus target
Current Price $13.91
Consensus Target $16.8
Bull Target $18.0
Bear Target $15.0
Analysts Covering 5
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
3
Hold
0
Sell
0
52-Week Low $6.25
52-Week High $15.89
YTD Return +93.0%
FUNDAMENTALS
Market Cap $1B
P/E Ratio (TTM) 17.8x
Forward P/E 15.4x
EPS (TTM) $0.78
PEG Ratio 1.78
Dividend Yield N/A
Revenue (TTM) $582M
Profit Margin 9.4%
52-WEEK RANGE
52-Week Low $6.25
52-Week High $15.89
Current Price $13.91
Bear Target $15.0
Bull Target $18.0
● Now $13.91 ● Target $16.8
TRADING DATA
Avg Volume 759K
YTD Return +93.0%
Analyst Count 5
Consensus Buy
Upside to Target +20.7%
Last Updated 2026-08-13

ANALYST SUMMARY

Bioventus Inc. (BVS) is currently trading at $13.91 with a Wall Street consensus price target of $16.8, implying potential upside of 20.7% over the next 12 months. 5 analysts currently cover BVS, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $18.0, while the most cautious has a target of $15.0.

BVS operates in the Healthcare sector with a market capitalisation of $1B. The stock is up 93.0% year-to-date and is currently trading near the upper end of its 52-week range of $6.25 – $15.89.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for BVS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Canaccord Genuity - Reiterated
Buy → Buy 2026-06-16 Building track record
Barrington Research - Reiterated
Outperform → Outperform 2026-05-22 Building track record
Barrington Research - Reiterated
Outperform → Outperform 2026-03-06 Building track record
Craig-Hallum - Reiterated
Buy → Buy 2026-03-06 Building track record
Barrington Research ● Initiated
Outperform 2026-02-09 Building track record
Cantor Fitzgerald ● Initiated
Overweight 2025-07-07 40% win rate (10 calls)
Canaccord Genuity - Reiterated
Buy → Buy 2025-03-17 Building track record
JP Morgan ↑ Upgrade
Underweight → Neutral 2024-12-17 43% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
67
out of 100
Coverage depth
14/30
Consensus clarity
26/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →